U.S., Oct. 21 -- ClinicalTrials.gov registry received information related to the study (NCT07218380) titled 'A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract' on Oct. 09.
Brief Summary: The purpose of this study is to test a new medicine, vepugratinib, in comparison with placebo, to see if it is safe and can help people with a bladder cancer that is advanced or has spread.
Vepugratinib and placebo will be administered in combination with existing standard of care (SOC) therapy.
Study participation could last up to approximately 6 years.
Study Start Date: Nov., 2025
Study Type: INTERVENTIONAL
Condition:
Carcinoma, Transitional Cell
Urinary Bladder Neoplasms
Neoplasm Metastasis
Intervention:
DRUG: ...